If approved, the new flu shot could be on the market in time for the 2026-27 flu season.
Taimy Alvarez/AP
The Food and Drug Administration will review pharmaceutical company Moderna’s application for a flu vaccine made with mRNA technology after all.
The Trump administration previously refused to review the company’s application for a new flu vaccine, claiming last week that Moderna had failed to present an “adequate and well-controlled” study.
But the agency has reversed course, Moderna announced Wednesday.
Stay connected with free newsletters and updates from Washington’s fastest-growing newsroom.
Stay connected with free newsletters and updates from Washington’s fastest-growing newsroom.
Log into your account.
We sent a 4-digit code to . Enter the pin to confirm your account.
New code will be available in 1:00
We encountered an error with the passcode sent to . Please reenter your email.